Life Sciences Industry Report 2025 - Part 2

R&D
Life Sciences Industry Report 2025 pt2 cover

The pharmaceutical landscape in 2024 was undeniably shaped by the remarkable rise of GLP-1 receptor agonists.

Once primarily recognised for their role in managing type 2 diabetes, these therapies have surged into mainstream consciousness, fuelled by growing demand for weight management solutions and off-label applications. Nonetheless, such extraordinary demand has also posed significant challenges in supply chains and regulatory oversight.

Indeed, counterfeiters worldwide have exploited this landscape of demand and shortages to establish unregulated online “pharmacies” offering semaglutide products at minimal costs, adding to critical concerns around safety, regulation, and brand integrity. 

Simultaneously, the competitive landscape is evolving rapidly. New entrants are stepping into the GLP-1 market, intensifying the race to innovate and capture market share. This influx of competitors is set to reshape pricing dynamics, accessibility, and the trajectory of future research and development.

Our Life Sciences Industry Report 2025 aims to provide truly informed insight into an industry very much at the height of its discovery and development capabilities, on the precipice of truly impressive, paradigm shifting innovation and, vitally, paving the way to broader access to treatments that will permit better quality of life and patient outcomes overall.

We invite you to explore the insights and analysis within this report and join us in unpacking what the future holds for GLP-1 therapies in 2025, and beyond. Download Part 2 now.